BACKGROUND: The β(1)-adrenoceptor (β(1)AR) mediates cardiostimulatory effects of catecholamines in the heart. The Arg389Gly polymorphism of the β(1)AR gene has recently been shown to determine the responsiveness to catecholamines in vitro, and we previously reported that dobutamine induced an augmented contractile response in humans homozygous for the Arg389 allele. The aim of the present study was to evaluate whether the Arg389Gly β(1)AR gene polymorphism influences the responsiveness to β-blocker treatment on cardiac contractility. METHODS: We investigated 30 healthy male volunteers who were genotyped for the Arg389Gly polymorphism and subjected to modified dobutamine stress-echocardiography (DSE) with and without pretreatment withmetoprolol controlled release/extended release (CR/XL). Fractional shortening (FS) as a parameter for left-ventricular contractility and heart rate were measured. To control for pre- and afterload effects, rate corrected velocity of circumferential fiber shortening (Vcfc) was calculated. RESULTS: Homozygous Arg389 carriers had a significantly higher increase in contractility upon dobutamine stimulation than individuals carrying the Gly389 allele. Pretreatment with metoprolol CR/XL prior to DSE blunted the dobutamine-induced increase of FS and Vcfc in homozygous Arg389 carriers to the level of subjects carrying the Gly389 allele. In the latter group, metoprolol had a modest effect on the dobutamine-induced increase in FS at low concentrations of dobutamine, and no significant effect at peak stress (40 μg/kg/min of dobutamine). CONCLUSION: The responsiveness to β-blockers with respect to cardiac contractility is determined by the Arg389Gly β(1)AR gene polymorphism. These findings offer a molecular explanation for interindividual differences in the responsiveness to β-blocker treatment in humans.
RCT Entities:
BACKGROUND: The β(1)-adrenoceptor (β(1)AR) mediates cardiostimulatory effects of catecholamines in the heart. The Arg389Gly polymorphism of the β(1)AR gene has recently been shown to determine the responsiveness to catecholamines in vitro, and we previously reported that dobutamine induced an augmented contractile response in humans homozygous for the Arg389 allele. The aim of the present study was to evaluate whether the Arg389Gly β(1)AR gene polymorphism influences the responsiveness to β-blocker treatment on cardiac contractility. METHODS: We investigated 30 healthy male volunteers who were genotyped for the Arg389Gly polymorphism and subjected to modified dobutamine stress-echocardiography (DSE) with and without pretreatment with metoprolol controlled release/extended release (CR/XL). Fractional shortening (FS) as a parameter for left-ventricular contractility and heart rate were measured. To control for pre- and afterload effects, rate corrected velocity of circumferential fiber shortening (Vcfc) was calculated. RESULTS: Homozygous Arg389 carriers had a significantly higher increase in contractility upon dobutamine stimulation than individuals carrying the Gly389 allele. Pretreatment with metoprolol CR/XL prior to DSE blunted the dobutamine-induced increase of FS and Vcfc in homozygous Arg389 carriers to the level of subjects carrying the Gly389 allele. In the latter group, metoprolol had a modest effect on the dobutamine-induced increase in FS at low concentrations of dobutamine, and no significant effect at peak stress (40 μg/kg/min of dobutamine). CONCLUSION: The responsiveness to β-blockers with respect to cardiac contractility is determined by the Arg389Gly β(1)AR gene polymorphism. These findings offer a molecular explanation for interindividual differences in the responsiveness to β-blocker treatment in humans.
Authors: M D Cheitlin; J S Alpert; W F Armstrong; G P Aurigemma; G A Beller; F Z Bierman; T W Davidson; J L Davis; P S Douglas; L D Gillam Journal: Circulation Date: 1997-03-18 Impact factor: 29.690
Authors: Steven G Terra; Daniel F Pauly; Craig R Lee; J Herbert Patterson; Kirkwood F Adams; Richard S Schofield; Bernadette S Belgado; Karen K Hamilton; Juan M Aranda; James A Hill; Hossein N Yarandi; Joseph R Walker; Michael S Phillips; Craig A Gelfand; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2005-03 Impact factor: 6.875
Authors: Issam Zineh; Amber L Beitelshees; Andrea Gaedigk; Joseph R Walker; Daniel F Pauly; Kathleen Eberst; J Steven Leeder; Michael S Phillips; Craig A Gelfand; Julie A Johnson Journal: Clin Pharmacol Ther Date: 2004-12 Impact factor: 6.875
Authors: Lu Chen; Deborah Meyers; George Javorsky; Darryl Burstow; Pakorn Lolekha; Margaret Lucas; Annalese B T Semmler; Santiyagu M Savarimuthu; Kwun M Fong; Ian A Yang; John Atherton; Andrew J Galbraith; William A Parsonage; Peter Molenaar Journal: Pharmacogenet Genomics Date: 2007-11 Impact factor: 2.089
Authors: T Rau; H Wuttke; L M Michels; U Werner; K Bergmann; M Kreft; M F Fromm; T Eschenhagen Journal: Clin Pharmacol Ther Date: 2008-11-26 Impact factor: 6.875
Authors: Jacqueline Savva; Azhar Maqbool; Hazel L White; Stacey L Galloway; Nadira Y Yuldasheva; Stephen G Ball; Robert M West; Rudolf A De Boer; Dirk J Van Veldhuisen; Anthony J Balmforth Journal: J Card Fail Date: 2009-02-12 Impact factor: 5.712
Authors: Eva S Kehmeier; Wolfgang Lepper; Martina Kropp; Christian Heiss; Ulrike Hendgen-Cotta; Jan Balzer; Mirja Neizel; Christian Meyer; Marc W Merx; Pablo E Verde; Christian Ohmann; Gerd Heusch; Malte Kelm; Tienush Rassaf Journal: Clin Res Cardiol Date: 2012-05-06 Impact factor: 5.460
Authors: Sara L Van Driest; Lynn A Sleeper; Bruce D Gelb; Shaine A Morris; Harry C Dietz; Geoffrey A Forbus; Elizabeth Goldmuntz; Arvind Hoskoppal; Jeanne James; Teresa M Lee; Jami C Levine; Jennifer S Li; Bart L Loeys; Larry W Markham; Josephina A N Meester; Seema Mital; Jonathan D Mosley; Aaron K Olson; Marjolijn Renard; Christian M Shaffer; Angela Sharkey; Luciana Young; Ronald V Lacro; Dan M Roden Journal: J Pediatr Date: 2020-07 Impact factor: 4.406